Tc Biopharm Plc Stock Debt To Equity

TCBPW Stock  USD 0.02  0.0005  3.03%   
TC BioPharm plc fundamentals help investors to digest information that contributes to TC BioPharm's financial success or failures. It also enables traders to predict the movement of TCBPW Stock. The fundamental analysis module provides a way to measure TC BioPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TC BioPharm stock.
Last ReportedProjected for Next Year
Debt To Equity 0.56  0.57 
Debt To Equity is likely to climb to 0.57 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

TC BioPharm plc Company Debt To Equity Analysis

TC BioPharm's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Current TC BioPharm Debt To Equity

    
  0.57  
Most of TC BioPharm's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TC BioPharm plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

TCBPW Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for TC BioPharm is extremely important. It helps to project a fair market value of TCBPW Stock properly, considering its historical fundamentals such as Debt To Equity. Since TC BioPharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TC BioPharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TC BioPharm's interrelated accounts and indicators.
0.470.05-0.490.23-0.380.6-0.260.410.620.180.53-0.46-0.30.53-0.15
0.47-0.54-0.97-0.1-0.030.02-0.960.960.44-0.030.9-0.890.150.0-0.55
0.05-0.540.430.85-0.780.680.49-0.74-0.530.81-0.150.12-0.810.710.91
-0.49-0.970.430.060.13-0.010.94-0.91-0.47-0.02-0.870.88-0.150.00.53
0.23-0.10.850.06-0.880.870.06-0.37-0.540.990.34-0.35-0.960.910.87
-0.38-0.03-0.780.13-0.88-0.760.00.220.39-0.9-0.390.430.86-0.78-0.68
0.60.020.68-0.010.87-0.760.06-0.2-0.180.810.41-0.36-0.920.990.67
-0.26-0.960.490.940.060.00.06-0.9-0.3-0.03-0.870.88-0.170.050.48
0.410.96-0.74-0.91-0.370.22-0.2-0.90.58-0.310.74-0.720.4-0.23-0.75
0.620.44-0.53-0.47-0.540.39-0.18-0.30.58-0.580.15-0.10.54-0.26-0.78
0.18-0.030.81-0.020.99-0.90.81-0.03-0.31-0.580.4-0.43-0.940.860.83
0.530.9-0.15-0.870.34-0.390.41-0.870.740.150.4-0.99-0.30.41-0.13
-0.46-0.890.120.88-0.350.43-0.360.88-0.72-0.1-0.43-0.990.28-0.370.11
-0.30.15-0.81-0.15-0.960.86-0.92-0.170.40.54-0.94-0.30.28-0.94-0.87
0.530.00.710.00.91-0.780.990.05-0.23-0.260.860.41-0.37-0.940.72
-0.15-0.550.910.530.87-0.680.670.48-0.75-0.780.83-0.130.11-0.870.72
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

TCBPW Total Stockholder Equity

Total Stockholder Equity

2.82 Million

At this time, TC BioPharm's Total Stockholder Equity is fairly stable compared to the past year.

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

TCBPW Fundamentals

About TC BioPharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze TC BioPharm plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.